[4-methyl-4-[4-(N-phenylanilino)-1-piperidyl]-1-piperidyl]-(1-naphthyl)methanone

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: [4-methyl-4-[4-(N-phenylanilino)-1-piperidyl]-1-piperidyl]-(1-naphthyl)methanone
• 英文别名: [4-methyl-4-[4-(N-phenylanilino)piperidin-1-yl]piperidin-1-yl]-naphthalen-1-ylmethanone
• 化学式: C₃₄H₃₇N₃O
• 分子量: 503.687
• InChiKey: CWHJFZWERDLNIU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  7.3
• 重原子数：
  38
• 可旋转键数：
  5
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  26.8
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  4-diphenylaminopiperidine-1-carboxylic acid tert-butyl ester 在 titanium(IV) isopropylate 、 O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate 、 N,N-二异丙基乙胺 、 三氟乙酸 作用下， 以 四氢呋喃 、 乙醚 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 41.0h， 生成 [4-methyl-4-[4-(N-phenylanilino)-1-piperidyl]-1-piperidyl]-(1-naphthyl)methanone
  参考文献：
  名称：

  Orally Bioavailable Competitive CCR5 Antagonists

  摘要：

  The chemokine receptor CCR5 plays an important role in inflammatory and autoimmune disorders as well as in transplant rejection by affecting the trafficking of effector T cells and monocytes to diseased tissues. Antagonists of CCR5 are believed to be of potential therapeutic value for the disorders mentioned above and HIV infection. Here we report on the structure-activity relationship of a new series of highly potent and selective competitive CCR5 antagonists. While all compounds tested were inactive on rodent CCR5, this series includes compounds that cross-react with the cynomolgus monkey (cyno) receptor. One of these compounds, i.e., 26n, has good PK properties in cynos, and its overall favorable profile makes it a promising candidate for in vivo profiling in transplantation and other disease models.

  DOI：

  10.1021/jm031046g

文献信息

• Orally Bioavailable Competitive CCR5 Antagonists
  作者：Gebhard Thoma、François Nuninger、Marc Schaefer、Kayhan G. Akyel、Rainer Albert、Christian Beerli、Christian Bruns、Eric Francotte、Marcel Luyten、Duncan MacKenzie、Lukas Oberer、Markus B. Streiff、Trixie Wagner、Hansrudolf Walter、Gisbert Weckbecker、Hans-Guenter Zerwes

  DOI：10.1021/jm031046g

  日期：2004.4.1

  The chemokine receptor CCR5 plays an important role in inflammatory and autoimmune disorders as well as in transplant rejection by affecting the trafficking of effector T cells and monocytes to diseased tissues. Antagonists of CCR5 are believed to be of potential therapeutic value for the disorders mentioned above and HIV infection. Here we report on the structure-activity relationship of a new series of highly potent and selective competitive CCR5 antagonists. While all compounds tested were inactive on rodent CCR5, this series includes compounds that cross-react with the cynomolgus monkey (cyno) receptor. One of these compounds, i.e., 26n, has good PK properties in cynos, and its overall favorable profile makes it a promising candidate for in vivo profiling in transplantation and other disease models.